Brigatinib, again to phuket, for he marina or bouguer, codename: AP26113) is a tyrosine kinase potent inhibitors.On April 28, 2017, and on behalf of, the United States listed on the FDA's accelerated approval, used in the treatment of azole to help during the disease after treatment progress or intolerance of ALK positive patients with locally advanced or static non-small cell lung cancer.Cloth and for inhibit ALK and ALK fusion protein, thereby inhibiting tumor growth.For in vitro and in vivo experiments, and also showed good inhibitory effect.Therefore, it has successively won the American FDA issued by the qualification of cognizance and orphan drug breakthrough treatments.
Cloth plus for Nick clothing ALK caused by mutant of grams for resistance, resistance to a variety of kinase (including ALK, ROS1, insulin-like growth factor 1 receptor, PLT - 3) and the lack of surface growth factor receptor (EGFR) and the activity of point mutations.Cloth and for, inhibition of ALK bick azole for 12 times higher, have very high resistance to ALK mutants, thus can be used in the treatment of azole to help, disease progression after treatment or intolerance of ALK positive patients with metastatic non-small-cell lung cancer (NSCLC).
Indications: for the patients with tumor
Specification: 90 mg * 30 grains
Retail price: $250
Note: Brigatinib as: buji he marina or bouguer for